Cargando…

Baseline and Breakthrough Resistance Mutations in HCV Patients Failing DAAs

Sustained virologic response rates have increased dramatically following direct acting antiviral (DAA) therapy in chronic HCV infection. However, resistance-associated substitutions (RASs) may occur either prior to DAA or following drug exposure. The aim of this study was to determine RASs in DAA tr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Paolucci, Stefania, Premoli, Marta, Novati, Stefano, Gulminetti, Roberto, Maserati, Renato, Barbarini, Giorgio, Sacchi, Paolo, Piralla, Antonio, Sassera, Davide, De Marco, Leone, Girello, Alessia, Mondelli, Mario U., Baldanti, Fausto
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2017
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5700050/ https://www.ncbi.nlm.nih.gov/pubmed/29167469 http://dx.doi.org/10.1038/s41598-017-15987-1

Ejemplares similares

Baseline Amino Acid Substitutions in the NS5A ISDR and PKR Binding Domain of Hepatitis C and Different Fibrosis Levels and Levels of Development of Hepatocellular Carcinoma in Patients Treated with DAAs
por: Paolucci, Stefania, et al.
Publicado: (2020)

Viral dynamics among HCV infected patients with different genotypes treated with genotypic specific or pan-genotypic direct-acting antiviral agent combinations
por: Paolucci, Stefania, et al.
Publicado: (2019)

Naturally occurring resistance mutations to inhibitors of HCV NS5A region and NS5B polymerase in DAA treatment-naïve patients
por: Paolucci, Stefania, et al.
Publicado: (2013)

Naturally occurring mutations to HCV protease inhibitors in treatment-naïve patients
por: Paolucci, Stefania, et al.
Publicado: (2012)

EBV DNA increase in COVID-19 patients with impaired lymphocyte subpopulation count
por: Paolucci, Stefania, et al.
Publicado: (2021)

HIV integrase variability and genetic barrier in antiretroviral naïve and experienced patients
por: Piralla, Antonio, et al.
Publicado: (2011)

Correlations between atazanavir C(trough )and hyperbilirubinemia: a case report
por: Uglietti, Alessia, et al.
Publicado: (2009)

The impact of viral respiratory infections in the first year post-transplant period of pediatric hematopoietic stem cell transplant (HSCT) recipients
por: Piralla, Antonio, et al.
Publicado: (2016)

Persistent rhinovirus infection in pediatric hematopoietic stem cell transplant recipients with impaired cellular immunity
por: Piralla, Antonio, et al.
Publicado: (2015)

Frequency of respiratory virus infections and next-generation analysis of influenza A/H1N1pdm09 dynamics in the lower respiratory tract of patients admitted to the ICU
por: Piralla, Antonio, et al.
Publicado: (2017)

FilmArray™ GI panel performance for the diagnosis of acute gastroenteritis or hemorragic diarrhea
por: Piralla, Antonio, et al.
Publicado: (2017)

Deep-sequencing study of HCV G4a resistance-associated substitutions in Egyptian patients failing DAA treatment
por: Amer, Fatma, et al.
Publicado: (2019)

Efficacy and tolerability of DAAs in HCV-monoinfected and HCV/HIV-coinfected patients with psychiatric disorders
por: de Gennaro, Nicolò, et al.
Publicado: (2020)

Treatment and re-treatment results of HCV patients in the DAA era
por: Piecha, Felix, et al.
Publicado: (2020)

Persistence of Cryoglobulinemic Vasculitis after DAA Induced HCV Cure
por: Danishwar, Mahmood, et al.
Publicado: (2022)

Updated View on Kidney Transplant from HCV-Infected Donors and DAAs
por: Fabrizi, Fabrizio, et al.
Publicado: (2021)

Survival of HIV/HCV co-infected patients before introduction of HCV direct acting antivirals (DAA)
por: Dold, L., et al.
Publicado: (2019)

Enterovirus (EV)-D68 in Pediatric Patients with Respiratory Tract Infection: the Circulation of new B3 Clade in Italy
por: Piralla, Antonio, et al.
Publicado: (2017)

Severe acute respiratory syndrome coronavirus 2 RNA contamination of inanimate surfaces and virus viability in a health care emergency unit
por: Colaneri, M., et al.
Publicado: (2020)

HCV and kidney transplant in the era of new direct-acting antiviral agents (DAAs)
por: La Manna, Gaetano
Publicado: (2018)

Impact of DAA Treatment on Cardiovascular Disease Risk in Chronic HCV Infection: An Update
por: Roguljic, Hrvoje, et al.
Publicado: (2021)

HCV compliance and treatment success rates are higher with DAAs in structured HCV clinics compared to general hepatology clinics
por: Chehl, Navdeep, et al.
Publicado: (2019)

Contemporary HCV pangenotypic DAA treatment protocols are exclusionary to real world HIV-HCV co-infected patients
por: Maughan, A., et al.
Publicado: (2019)

Restoration of HCV-Specific Immune Responses with Antiviral Therapy: A Case for DAA Treatment in Acute HCV Infection
por: Casey, Julia L., et al.
Publicado: (2019)

Gamma-Delta T-Cell Phenotype and Function in DAA-Treated HIV-HCV Co-Infected and HCV-Mono-Infected Subjects
por: Bono, Valeria, et al.
Publicado: (2022)

Oral Zinc Supplementation Decreases the Risk of HCC Development in Patients With HCV Eradicated by DAA
por: Hosui, Atsushi, et al.
Publicado: (2021)

Late Relapse and Reinfection in HCV Patients Treated with Direct-Acting Antiviral (DAA) Drugs
por: Minosse, Claudia, et al.
Publicado: (2021)

Longitudinal assessment of HCV core antigen kinetics to monitor therapeutic response in the age of DAAs
por: Ponnuvel, Suresh, et al.
Publicado: (2023)

HCV core antigen is an alternative marker to HCV RNA for evaluating active HCV infection: implications for improved diagnostic option in an era of affordable DAAs
por: Wasitthankasem, Rujipat, et al.
Publicado: (2017)

Molecular epidemiology of influenza B virus among hospitalized pediatric patients in Northern Italy during the 2015-16 season
por: Piralla, Antonio, et al.
Publicado: (2017)

Barriers to treatment of failed or interferon ineligible patients in the era of DAA: single center study
por: Seo, Kwang Il, et al.
Publicado: (2017)

Occult hepatitis B in patients with cancer during immunotherapy with or without chemotherapy: A real-life retrospective single-center cohort study
por: Lasagna, Angioletta, et al.
Publicado: (2023)

SARS‐CoV‐2 infections in pediatric patients: A comparison of three pandemic waves
por: Rovida, Francesca, et al.
Publicado: (2022)

Pre-Existing HCV Variants Resistant to DAAs and Their Sensitivity to PegIFN/RBV in Chinese HCV Genotype 1b Patients
por: Zhang, Yu, et al.
Publicado: (2016)

Immunological and Clinical Impact of DAA-Mediated HCV Eradication in a Cohort of HIV/HCV Coinfected Patients: Monocentric Italian Experience
por: Marino, Andrea, et al.
Publicado: (2021)

Longitudinal Assessment of Multiple Immunological and Inflammatory Parameters during Successful DAA Therapy in HCV Monoinfected and HIV/HCV Coinfected Subjects
por: Zuccalà, Paola, et al.
Publicado: (2022)

Linkage and retention in HCV care for HIV‐infected populations: early data from the DAA era
por: Sacks‐Davis, Rachel, et al.
Publicado: (2018)

Timing of DAA Initiation After Curative Treatment and Its Relationship with the Recurrence of HCV-Related HCC
por: Gao, Xiuzhu, et al.
Publicado: (2020)

Different Kinetics of HBV-DNA and HBsAg in HCV Coinfected Patients during DAAs Therapy
por: Colombatto, Piero, et al.
Publicado: (2022)

HIV-reservoir size is not affected either by HCV coinfection or by direct acting antivirals (DAAs) therapy
por: Álvarez, Beatriz, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_vgt9bnbfp7p10ipmo5d70u9d7g